How this company is disrupting biotech with 30-somethings and industry vets


Three young execs and a trio of experienced veterans are trying to move drugs attacking genetic diseases to market faster with a lean model.

Previous Plymouth Meeting dental support organization makes major acquisition in Texas
Next Johnson & Johnson settlement on surgical mesh includes $2.8M for Arizona